Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in several key conferences in June 2024. The company will present its developments in RNAi molecule platforms for glaucoma at the 16th European Glaucoma Society Congress on June 2. Arrowhead will also discuss fazirsiran treatment for liver disease at the EASL Congress on June 7, and ARO-C3 for complement C3 targeting at the APCN on June 13. Additionally, Arrowhead will present insights into its RNA therapeutics at the ADA Scientific Sessions on June 24 and the RNA Therapeutics Conference from June 26-28. Presentation materials will be available on the Arrowhead website.
- Arrowhead Pharmaceuticals will present at multiple high-profile healthcare and scientific conferences in June 2024, potentially increasing visibility within the medical and investment communities.
- The company showcases a diverse pipeline, including RNAi therapeutics for glaucoma, liver disease, and metabolic conditions.
- Participation in the Jefferies Global Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference offers opportunities for networking with potential investors and partners.
- The PR does not provide specific data on clinical trial progress or financial performance, which may concern investors seeking concrete updates.
- There is no mention of new approvals or partnerships, key drivers for stock performance.
16th European Glaucoma Society (EGS) Congress – June 1-4, 2024
Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma
Date/Time: June 2, 2024, 10:30 a.m. IST
Session: Poster Section
Jefferies Global Healthcare Conference – June 5-6, 2024
Type: Fireside Chat Presentation
Date/Time: June 5, 2024, 12:30 p.m. EDT
European Association for the Study of the Liver (EASL) Congress 2024 – June 5-8, 2024
Title: Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease
Date: June 7, 2024
Type: Poster
Title: Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease
Date: June 7, 2024
Type: Poster
Goldman Sachs 45th Annual Global Healthcare Conference – June 10-13, 2024
Type: Fireside Chat Presentation
Date/Time: June 12, 2024, 4:00 p.m. EDT
22nd Asian Pacific Congress of Nephrology (APCN 2024) – June 13-16, 2024
Title: Safety, Tolerability, and Pharmacodynamics of ARO-C3, a Subcutaneously Administered Investigational RNA-interference Therapeutic Targeting Complement C3 in Adult Healthy Volunteers
Date: June 13, 2024
Type: Poster
American Diabetes Association (ADA) 84th Scientific Sessions – June 21-24, 2024
Title: Liver-specific silencing of INHBE with ARO-INHBE, an siRNA therapeutic, for metabolic diseases
Date: June 24, 2024
Type: Poster
6th Annual RNA Therapeutics Conference | Symposium 2024 From Concept to Clinic – June 26-28, 2024
Title: Rank order TRiMTM activity correlates with RISC loading and can be enhanced by cPrp modification
Date/Time: June 28, 2024, 1:00-2:30 p.m. EDT
Session: Poster Session II
Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240531115413/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.
FAQ
What will Arrowhead Pharmaceuticals present at the 16th European Glaucoma Society Congress on June 2, 2024?
When is Arrowhead Pharmaceuticals presenting at the Jefferies Global Healthcare Conference?
What are the topics of Arrowhead Pharmaceuticals' presentations at the EASL Congress 2024?
When is Arrowhead Pharmaceuticals presenting at the Goldman Sachs Annual Global Healthcare Conference?
What will Arrowhead Pharmaceuticals discuss at the Asian Pacific Congress of Nephrology 2024?
What will Arrowhead Pharmaceuticals present at the American Diabetes Association Scientific Sessions on June 24, 2024?
When is Arrowhead Pharmaceuticals presenting at the 6th Annual RNA Therapeutics Conference?
